Commercialization of Human Visceral Adipocytes

描述（由申请人提供）：美国正在经历肥胖[1]和相关合并症（如2型糖尿病）的流行性上升。流行病学研究表明，这些合并症与内脏（腹腔内）脂肪沉积特别相关。为了阐明这种关联，必须为研究人员提供理想的模型，即人类内脏脂肪细胞。Zen-Bio，Inc.将通过开发一种特征化的、商业上可获得的培养人内脏前脂肪细胞来源来解决这一需求。初步数据表明，内脏前脂肪细胞不同于皮下脂肪细胞，需要个性化的培养技术。该提案的目的1将寻求通过改善组织的机械和酶促溶解以及去除污染细胞类型来最大化从小实体组织样品中回收内脏前脂肪细胞。目标2将专注于通过开发生长因子鸡尾酒和确定最佳接种密度将内脏前脂肪细胞扩增至至少2000万个细胞。目标3将评估两个参数，供体的高龄或死后时间的增加，对总细胞回收率、活力和/或生长特性的负面影响。第一阶段SBIR专注于开发内脏前脂肪细胞培养所需的专门技术。在第二阶段，我们将专注于将这些细胞分化为成熟的内脏脂肪细胞，然后优化基于细胞的测定以有效利用这些细胞。

DESCRIPTION (provided by applicant): The US is experiencing an epidemic rise in obesity [1] and related co-morbidities, such as type 2 diabetes. Epidemiological studies demonstrate that these co-morbidities are specifically correlated with visceral (intra-abdominal) fat deposition. To elucidate this association, an ideal model, human visceral adipocytes, must be made available to researchers. Zen-Bio, Inc. will address this need by developing a characterized, commercially accessible source of cultured human visceral preadipocytes. Preliminary data indicate that visceral preadipocytes are distinct from subcutaneous adipocytes, requiring individualized culturing techniques. Aim 1 of this proposal will seek to maximize visceral preadipocyte recovery from small solid tissue samples by improving mechanical and enzymatic dissolution of tissue and removal of contaminating cell types. Aim 2 will focus on expansion of the visceral preadipocytes to at least 20 million cells by developing growth factor cocktails and determining optimal seeding densities. Aim 3 will assess two parameters, advanced age of a donor or increased time post-mortem, for negative impact on total cell recovery, viability and/or growth characteristics. This Phase I SBIR concentrates on developing specialized techniques needed for culture of visceral preadipocytes. In Phase II we will focus on differentiating these cells into mature visceral adipocytes, followed by optimization of cell-based assays to effectively utilize these cells.